Drugs / metrotrexate
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05274139 | Mar 2017 → Mar 2019 | primary central nervous system lymphoma | Mingzhi Zhang | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01960192 | Jun 2012 → Jun 2016 | primary central nervous system lymphoma | Mingzhi Zhang | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | metrotrexate | “HD-MTX-Ara-C regimen high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine” NCT05274139 ↗1“high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine 1g/m2 bid d2-3.” NCT01960192 ↗ |
| Route | Intravenous | “high-does metrotrexate 3.5g/m2 d1 ivgtt 6h” NCT01960192 ↗ |